▶주메뉴 바로가기
▶본문 바로가기
Celltrion Healthcare announced on March 11 that it won bids to supply Remsima and Truxima to two Southeast Asian countries at the end of last year. For this year, the company will be exclusively sup...
Stonebridge Ventures, spun-off from Korean private equity firm Stonebridge Capital, will invest more in the bio industry this year, according to industry sources on March 8. “Recently, we saw growin...
Korean biopharmaceutical firm Samsung Bioepis will spend 180.4 billion won (US$159.70) to build a new research and development center, its parent company said Thursday. The investment cost accoun...
Daewoong Pharmaceutical announced on March 6 that it posted sales of 1.31 trillion won (US$ 1.16 billion) last year. It has became one of the few Korean pharma firms to reach the milestone. Three ot...
SillaJen aims to secure around 220 billion won (US$194.89 million) fresh funds through issuing convertible bonds, according to industry sources on March 7. It has picked Kium Securities to organize ...
Stock exchange operator Korea Exchange has blocked condom maker Bio Genetics from getting representation on Kyung Nam Pharm’s board, according to industry sources on Mar. 6. Bio Genetics, which boug...
Korean biopharmaceutical firm Samsung Bioepis said on March 5 it has won approval from European authorities for the sale of mass dosages of its biosimilar drug Ontruzant. The European Medicines A...
Hypertension drugs gained unwanted attention in South Korea last year: More than 170 generic drugs sold by 76 local drugmakers were recalled by the Drug Ministry for their inclusion of valsartan, a c...
Ildong Pharmaceutical’s multivitamin series Aronamin was the best-selling over the counter drug for the third consecutive year in 2018. OTC drugs can be purchased directly at medical stores without ...
Korean cosmetics manufacturer Kolmar Korea has decided to issue corporate bonds worth 100 billion won (US$89.35 million), according to industry sources on Feb. 28. Mirae Asset Daewoo is organizing i...
Celltrion Pharm, the generic arm of Celltrion, announced on Feb. 27 that it has decided to inject 58.2 billion won for establishing its Remsima SC production facility at its plant in Cheongju, North ...
SK Biopharmaceuticals, the new drug development unit of Korea’s telecom-to-energy conglomerate SK Group, is considering exporting its drug candidate Cenobamate to Japan, according to industry sources...
Hong Kong-based global private equity firm Anchor Equity Partners plans to sell its 47 percent stake in Korean top drug retailer Geoyoung, according to industry sources on Feb. 25. The PEF has repor...
Kyung Nam Pharm, a local drug maker known for its vitamin supplement product Lemona, is once again looking for an owner after failing to sign a deal with South Korean media company KMH Group in 2018....
Korean pharmaceutical company Yuhan announced on Feb. 20 that its sales reached 1.5 trillion won (US$1.3 billion) last year, up 4 percent from the previous year. Yuhan has now become the first Korea...
[Herald Interview] NYSE hopes to see more Korean firms listing in US
Watchdog orders banks to compensate investors for damages from Lime misselling
National Pension Service gains W72tr for 2020
Provisioning, relief measures to support S. Korean banks’ performance: Fitch
Once-hot P2P lending industry faces tough road ahead
SK Bioscience seeks up to W1.5tr in blockbuster IPO
S. Korean unicorns take big leap with greater global presence
[News Focus] Power struggle? FSC, BOK bicker over revision of payment settlement law
February 27, 2021
![[Herald Interview] NYSE hopes to see more Korean firms listing in US](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2021/02/26/20210226000217_0.jpg&md=20210226125435)
![[News Focus] Power struggle? FSC, BOK bicker over revision of payment settlement law](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2021/02/22/20210222000835_0.jpg&md=20210222175948)
